Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis.

Wu D, Hu M, Hong L, Hong S, Ding W, Min J, Fang G, Guo W.

Arch Gynecol Obstet. 2014 Sep;290(3):513-23. doi: 10.1007/s00404-014-3230-8. Epub 2014 Apr 13. Review.

PMID:
24728145
2.

Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density.

Sagsveen M, Farmer JE, Prentice A, Breeze A.

Cochrane Database Syst Rev. 2003;(4):CD001297. Review.

PMID:
14583930
3.

[A meta-analysis of preventing bone mineral loss in patients with endometriosis treated by gonadotrophin-releasing hormone analogues with add-back therapy].

Niu ZR, Yue XJ, Kong QY, Wang YF, Yao YQ.

Zhonghua Fu Chan Ke Za Zhi. 2013 May;48(5):338-43. Chinese.

PMID:
24016475
4.

Add-back therapy in the treatment of endometriosis-associated pain.

Zupi E, Marconi D, Sbracia M, Zullo F, De Vivo B, Exacustos C, Sorrenti G.

Fertil Steril. 2004 Nov;82(5):1303-8.

PMID:
15533351
5.

Gonadotrophin-releasing hormone analogues for pain associated with endometriosis.

Brown J, Pan A, Hart RJ.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD008475. doi: 10.1002/14651858.CD008475.pub2. Review.

PMID:
21154398
8.

Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.

DiVasta AD, Feldman HA, Sadler Gallagher J, Stokes NA, Laufer MR, Hornstein MD, Gordon CM.

Obstet Gynecol. 2015 Sep;126(3):617-27. doi: 10.1097/AOG.0000000000000964.

9.

Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.

Hornstein MD, Surrey ES, Weisberg GW, Casino LA.

Obstet Gynecol. 1998 Jan;91(1):16-24.

PMID:
9464714
11.

Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.

Surrey ES, Hornstein MD.

Obstet Gynecol. 2002 May;99(5 Pt 1):709-19.

PMID:
11978277
12.

Low-dose add-back therapy during postoperative GnRH agonist treatment.

Tsai HW, Wang PH, Huang BS, Twu NF, Yen MS, Chen YJ.

Taiwan J Obstet Gynecol. 2016 Feb;55(1):55-9. doi: 10.1016/j.tjog.2015.04.004.

13.
14.

A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.

Vercellini P, Trespidi L, Colombo A, Vendola N, Marchini M, Crosignani PG.

Fertil Steril. 1993 Jul;60(1):75-9.

PMID:
8513962
15.

Current approaches to optimizing the treatment of endometriosis in adolescents.

Laufer MR.

Gynecol Obstet Invest. 2008;66 Suppl 1:19-27. doi: 10.1159/000148027. Epub 2008 Oct 21. Review.

PMID:
18936548
16.

Extending the treatment boundaries: Zoladex and add-back.

Schlaff WD.

Int J Gynaecol Obstet. 1999 Feb;64 Suppl 1:S25-31. Review.

PMID:
10096462
17.

Medical management of endometriosis: a systematic review.

Schroder AK, Diedrich K, Ludwig M.

IDrugs. 2004 May;7(5):451-63. Review.

PMID:
15154107
18.

Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.

Regidor PA, Regidor M, Schmidt M, Ruwe B, Lübben G, Förtig P, Kienle E, Schindler AE.

Gynecol Endocrinol. 2001 Jun;15(3):202-9.

PMID:
11447732
19.
20.

Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.

Divasta AD, Laufer MR, Gordon CM.

J Pediatr Adolesc Gynecol. 2007 Oct;20(5):293-7.

Supplemental Content

Support Center